AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 83 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $27,000 | -74.3% | 10,900 | -28.8% | 0.00% | – |
| Q1 2022 | $105,000 | +9.4% | 15,300 | +44.3% | 0.00% | – |
| Q1 2021 | $96,000 | -45.5% | 10,600 | -59.7% | 0.00% | -100.0% |
| Q4 2020 | $176,000 | -22.8% | 26,300 | -41.9% | 0.00% | 0.0% |
| Q3 2020 | $228,000 | -27.8% | 45,300 | +15.9% | 0.00% | -50.0% |
| Q2 2020 | $316,000 | -78.7% | 39,100 | -79.1% | 0.00% | -81.8% |
| Q1 2020 | $1,486,000 | +230.2% | 187,200 | +213.8% | 0.01% | +266.7% |
| Q4 2019 | $450,000 | +248.8% | 59,654 | +91.9% | 0.00% | +200.0% |
| Q3 2019 | $129,000 | +892.3% | 31,078 | +935.9% | 0.00% | – |
| Q3 2018 | $13,000 | -96.1% | 3,000 | -90.6% | 0.00% | -100.0% |
| Q3 2017 | $336,000 | +5.3% | 32,000 | +10.7% | 0.00% | 0.0% |
| Q2 2017 | $319,000 | +398.4% | 28,900 | +337.9% | 0.00% | – |
| Q1 2017 | $64,000 | – | 6,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |